FDA Approves New Treatment for Rare Nerve Disorder
WASHINGTON, D.C. — On Friday, the FDA approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for treating chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. This approval marks a significant development in …
FDA Approves New Treatment for Rare Nerve Disorder Read More